ClinicalTrials.gg
RecruitingNCT07719712POCDTURMSTUDUpdated Jul 22, 2026

Cognitive Dysfunction and Delirium After TUR-M in Elderly Patients

An observational study in Postoperative Delirium, Postoperative Cognitive Dysfunction and Cognitive Dysfunction, sponsored by Muğla Sıtkı Koçman University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Muğla Sıtkı Koçman University · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
65 Years and older
Sex
All
01

Study summary

Elderly patients undergoing transurethral resection are at increased risk of postoperative cognitive dysfunction (POCD) and delirium, which are associated with prolonged hospital stay, increased morbidity, and decreased quality of life. Identifying patients who are more likely to develop postoperative cognitive dysfunction or delirium remains a practical challenge in daily clinical practice. Better recognition of these patients may help tailor perioperative care and improve outcomes.

This prospective observational study aims to identify perioperative factors associated with POCD and delirium in elderly patients undergoing transurethral resection and to develop a clinically applicable risk prediction model. Cognitive function and delirium are assessed using the Montreal Cognitive Assessment (MoCA) and the Confusion Assessment Method (CAM).

Cognitive function and delirium will be evaluated using the Montreal Cognitive Assessment (MoCA) and the Confusion Assessment Method (CAM).

The results of this study may support clinicians in recognizing vulnerable patients earlier and may contribute to more individualized perioperative management.

Read the detailed description

Postoperative cognitive dysfunction (POCD) and delirium are frequently encountered in elderly patients after surgery and are linked to unfavorable clinical outcomes. Transurethral resection procedures, which are commonly performed in this age group, may further increase this risk due to both patient-related and perioperative factors.

In this prospective observational cohort, patients aged 65 years and older undergoing transurethral resection at Mugla Training and Research Hospital are followed to determine the incidence of POCD and delirium and to identify perioperative factors associated with their development.

Before surgery, demographic characteristics, comorbidities, frailty status, and baseline cognitive function are recorded. Baseline cognitive function is assessed using the Montreal Cognitive Assessment (MoCA). During surgery, the anesthesia technique, procedure duration, intraoperative hemodynamic changes, and perioperative events are recorded.

After surgery, cognitive function and delirium are assessed at predefined intervals using MoCA and the Confusion Assessment Method (CAM).

The primary objective is to identify factors independently associated with POCD and delirium. In addition, a prediction model is developed using multivariable logistic regression, and its performance is evaluated by receiver operating characteristic (ROC) analysis.

The results may help to better recognize patients at higher risk and support more tailored perioperative management strategies in elderly surgical populations.

02

Conditions studied

  • Postoperative Delirium
  • Postoperative Cognitive Dysfunction
  • Cognitive Dysfunction

Keywords

  • Postoperative Cognitive Dysfunction
  • Delirium
  • Transurethral Resection
03

In context

Emergence Delirium

751 studies on the registry are indexed under Emergence Delirium; 262 are open to participants now.

This study's planned enrollment of 150 is close to the median of 162 across 279 observational studies indexed under Emergence Delirium.

Browse Emergence Delirium studies →

Lead sponsor

Muğla Sıtkı Koçman University is the lead sponsor of 114 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients aged 65 years and older undergoing transurethral resection at Mugla Training and Research Hospital. These patients represent an elderly surgical population at risk for postoperative cognitive dysfunction and delirium. Participants are enrolled consecutively according to eligibility criteria and followed throughout the perioperative period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥65 years
  • Scheduled for transurethral resection procedure
  • I-III
  • Able to provide
  • Adequate cognitive function to complete preoperative assessment

Exclusion criteria

Exclusion Criteria:

  • Pre-existing diagnosis of dementia or severe cognitive impairment ( \<18)
  • Severe visual or hearing impairment preventing cognitive assessment
  • History of psychiatric disease requiring antipsychotic or sedative medication
  • Neurological disorders associated with increased delirium risk (e.g., Parkinson's disease, epilepsy)
  • Inability to complete study assessments
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testCognitive and Delirium Assessment (MoCA and CAM)

    Patients aged 65 years and older undergoing transurethral resection who are followed for the development of postoperative cognitive dysfunction and delirium.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative cognitive dysfunction and delirium

    Postoperative cognitive dysfunction and delirium assessed using the Montreal Cognitive Assessment (MoCA) and the Confusion Assessment Method (CAM). POCD is defined as a decline in MoCA score compared with baseline, and delirium is identified based on CAM criteria.

    Time frame: Baseline (preoperative) and postoperative days 1, 2, and 3

Secondary outcomes

  1. Risk factors associated with POCD and delirium

    Evaluation of perioperative variables (demographic characteristics, comorbidities, frailty status, anesthesia type, and intraoperative parameters) associated with the development of POCD and delirium. Evaluation of perioperative variables (demographic characteristics, comorbidities, frailty status, anesthesia type, and intraoperative parameters) associated with the development of POCD and delirium.

    Time frame: From baseline (preoperative) through postoperative day 3

  2. Performance of the predictive risk model

    Assessment of the predictive model for POCD and delirium using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis.

    Time frame: Through study completion (anticipated November 2026)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.

Of 181 non-industry observational studies under Emergence Delirium, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 5 months is below that.

Counting every sponsor, half of 181 studies reached it within 21 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 22, 2026
StartActual
Apr 5, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Nov 15, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719712
Responsible party
Eylem Yaşar (Anesthesiologist, Muğla Sıtkı Koçman University) — Principal investigator
First posted
Jul 22, 2026
Start date
Apr 5, 2026
Primary completion
Oct 1, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Jul 22, 2026

Study contacts

Eylem Yasar, MD
Contact
eylemtarakci@gmail.com
+905332392622
Melike Korkmaz Toker, MD
Contact
meltoker@gmail.com
+905054747098
Eylem Yasar, MD
principal investigator · Mugla Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion